SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15 (D)

 

of the

 

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported) October 16, 2019

AngioSoma, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada

333-170315

27-3480481

(State of Incorporation)

(Commission File Number)

(IRS Employer Identification Number)

 

2500 Wilcrest Drive, 3rd Floor
Houston, Texas 77042

(Address of principal executive offices)

 

832-781-8521

(Registrant’s telephone number, including area code)

www.AngioSoma.com

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

N/A

N/A

N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 
 

 

Item 7.01 Regulation FD Disclosure.

 

Effective October 16, 2019, AngioSoma, Inc. (‘The Company’, ‘We’, ‘Our’) executed a Settlement Agreement (the ‘Agreement’, the ‘Settlement’) of the litigation with David Summers. The Agreement covers all related claims and controversies between the Company, our wholly owned subsidiary, and Mr. Summers. In addition, the Agreement includes a mutual release and hold harmless of all parties related to the dispute that is resolved by the mediated Settlement.

 

Item 9.01 Financial Statements and Exhibits

 

Exhibit 99.1    Press Release dated October 22, 2019

 

 

 

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

AngioSoma, Inc.

 

 

Date: October 22, 2019

By: /s/ Alex K. Blankenship                       

 

Name: Alex K. Blankenship

Title: President and CEO